| US 7,547,687 B2 | ||
| Therapeutic treatment methods | ||
| Christopher L. Reading, San Diego, Calif. (US); Clarence N. Ahlem, San Diego, Calif. (US); Dominick L. Auci, San Diego, Calif. (US); Charles Dowding, San Diego, Calif. (US); James M. Frincke, Carlsbad, Calif. (US); Mei Li, San Diego, Calif. (US); Theodore M. Page, Carlsbad, Calif. (US); Dwight R. Stickney, Granite Bay, Calif. (US); Richard J. Trauger, Leucadia, Calif. (US); and Steven K. White, San Diego, Calif. (US) | ||
| Assigned to Hollis-Eden Pharmaceuticals, Inc., San Diego, Calif. (US) | ||
| Filed on Feb. 12, 2007, as Appl. No. 11/674,128. | ||
| Application 11/674128 is a continuation of application No. 10/728400, filed on Dec. 05, 2003, abandoned. | ||
| Application 10/728400 is a continuation in part of application No. 10/651515, filed on Aug. 28, 2003, abandoned. | ||
| Claims priority of provisional application 60/479257, filed on Jun. 17, 2003. | ||
| Claims priority of provisional application 60/408332, filed on Sep. 04, 2002. | ||
| Claims priority of provisional application 60/407146, filed on Aug. 28, 2002. | ||
| Prior Publication US 2007/0275938 A1, Nov. 29, 2007 | ||
| Int. Cl. A61K 31/568 (2006.01) | ||
| U.S. Cl. 514—169 [514/176] | 19 Claims |
1. A composition comprising one or more excipients and a compound having the structure
 wherein the dotted lines are optional double bonds;
R1 is —OH or an ester;
R2 is —H, —OH or an ester;
R3 is —H, —OH, a halogen or an ester;
R4 in the β-configuration is —OH, an ester or an amino acid and R4 in the α-configuration is —H or optionally substituted alkynyl;
R5 is —CH3 or —C2H5;
R10A is —OH or R10A is —H or —OH when R2 is —OH or an ester; and
R10B is a halogen.
|